dc.contributor.author | Stavem, Knut | |
dc.contributor.author | Heir, Trond | |
dc.contributor.author | Dammen, Toril | |
dc.contributor.author | Brønstad, Eivind | |
dc.contributor.author | Lerum, Tøri Vigeland | |
dc.contributor.author | Durheim, Michael Thomas | |
dc.contributor.author | Lund, Kristine Marie Aarberg | |
dc.contributor.author | Aarli, Bernt Bøgvald | |
dc.contributor.author | Einvik, Gunnar | |
dc.date.accessioned | 2022-09-12T09:29:16Z | |
dc.date.available | 2022-09-12T09:29:16Z | |
dc.date.created | 2022-08-12T11:48:19Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1664-0640 | |
dc.identifier.uri | https://hdl.handle.net/11250/3017178 | |
dc.description.abstract | Objective: To assess the trajectory of symptoms and symptom-defined post-traumatic stress disorder (PTSD) from 1.5 to 12 months after hospitalization for COVID-19 and determine risk factors for persistent symptoms and PTSD.
Methods: This was a prospective cohort study of consecutive patients discharged after hospitalization for COVID-19 before 1 June 2020 in six hospitals in Southern Norway. Symptom-defined PTSD was assessed by the post-traumatic stress disorder (PTSD) checklist for DSM-5 (PCL-5) at 1.5, 3 and/or 12 months after hospitalization, using DSM-5 criteria. Changes in PCL-5 symptom score and the prevalence of PTSD were analyzed with multivariable mixed models.
Results: In total, 388 patients were discharged alive, and 251 (65%) participated. Respondents had a mean (SD) age of 58.4 (14.2) years, and 142 (57%) were males. The prevalence of symptom-defined PTSD was 14, 8, and 9% at 1.5, 3, and 12 months, respectively. WHO disease severity for COVID-19 was not associated with PCL-5 scores. Female sex, lower age and non-Norwegian origin were associated with higher PCL-5 scores. The odds ratio (OR) (95%CI) for PTSD was 0.32 (0.12 to 0.83, p = 0.019) at 3 months and 0.38 (0.15 to 0.95, p = 0.039) at 12 months compared to 1.5 months. There was no association between PTSD and WHO severity rating.
Conclusions: The level of PTSD symptoms decreased from 1.5 to 3 months after hospitalization, but did not decrease further to 12 months, and there was no association between PTSD symptoms and COVID-19 disease severity. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Frontiers | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | The course and determinants of post-traumatic stress over 12 months after hospitalization for COVID-19 | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
dc.source.articlenumber | 931349 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.3389/fpsyt.2022.931349 | |
dc.identifier.cristin | 2042658 | |
dc.source.journal | Frontiers in Psychiatry | en_US |
dc.identifier.citation | Frontiers in Psychiatry. 2022, 13, 931349. | en_US |
dc.source.volume | 13 | en_US |